OPHTHETIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OPHTHETIC (OPHTHETIC).
Ophthalmic anesthetic; blocks sodium ion channels in nerve cell membranes, inhibiting depolarization and conduction of nerve impulses.
| Metabolism | Metabolized by plasma esterases (pseudocholinesterase) and hepatic esterases. |
| Excretion | Primarily renal excretion of unchanged drug and metabolites; ~80% eliminated in urine within 24 hours, with minor biliary/fecal excretion (<5%). |
| Half-life | Terminal elimination half-life is 2.5 to 3 hours (prolonged in renal impairment). |
| Protein binding | Approximately 55–65% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 2.5–3.0 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Ophthalmic administration results in systemic absorption; bioavailability is variable but significant due to absorption through conjunctiva and nasolacrimal duct. |
| Onset of Action | Ophthalmic administration: onset within minutes; peak effect at 1–2 hours. |
| Duration of Action | Ophthalmic effect lasts 4–8 hours; corneal anesthesia persists for about 30 minutes. |
1-2 drops of 0.5% solution into the affected eye(s) every 5-10 minutes for 3-5 doses prior to procedures; or 1-2 drops of 0.5% solution every 5-10 minutes for 2-3 doses for minor procedures.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Infants and children: 1-2 drops of 0.5% solution into the affected eye(s) every 5-10 minutes for 3-5 doses prior to procedures; or 1-2 drops every 5-10 minutes for 2-3 doses for minor procedures. |
| Geriatric use | Use with caution; reduce dose or frequency if excessive systemic absorption is a concern due to age-related reductions in hepatic and renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OPHTHETIC (OPHTHETIC).
| Breastfeeding | {"safety":"Considered compatible with breastfeeding. Systemic absorption after topical ocular administration is minimal (estimated <0.1% of dose), making transfer to breast milk negligible. No detectable concentrations in milk reported. M/P ratio is not available due to undetectable levels. Use with caution in nursing mothers only if clearly needed; avoid excessive or prolonged treatment.","m_p_ratio":"Not calculable (systemic levels below detection limits)"} |
| Teratogenic Risk | {"first_trimester":"Ophthalmic proparacaine is not systemically absorbed in significant amounts after topical ocular administration. Transient low concentrations do not reach fetal circulation; no direct teratogenic risk reported. However, inadvertent systemic absorption from excessive dosing could theoretically cause maternal toxicity (methemoglobinemia, CNS depression) that may indirectly affect the fetus. No human data indicate increased malformation risk.","second_trimester":"Same as first trimester; negligible systemic exposure limits fetal risk. No specific adverse fetal effects reported from topical ocular use.","third_trimester":"No fetal risk from topical use; very low systemic absorption prevents significant fetal exposure. Potential risk from maternal methemoglobinemia (rare) could cause fetal hypoxia if severe, but clinically insignificant with ophthalmic doses."} |
■ FDA Black Box Warning
Not for injection. Prolonged use may delay wound healing and cause corneal damage.
| Serious Effects |
Hypersensitivity to any component or other ester-type local anesthetics. Ophthalmic surgery requiring deep anesthesia.
| Precautions | Prolonged use may cause corneal epithelial defects, delayed wound healing, and potential corneal opacification and scarring. Avoid contamination of dropper tip. |
Loading safety data…
| Fetal Monitoring | {"required_monitoring":"No specific maternal or fetal monitoring required for routine ophthalmic use. In case of accidental systemic overdose or repeated administration, monitor for signs of methemoglobinemia (pulse oximetry with co-oximetry), CNS depression, cardiac arrhythmias. No fetal monitoring indicated unless maternal toxicity occurs."} |
| Fertility Effects | {"reproductive_impact":"No known effects on fertility or reproductive function. Topical ophthalmic anesthetics do not reach concentrations sufficient to influence gametogenesis or implantation. No animal or human data suggest impairment of fertility with ocular use."} |